prr on the nasdaq, page-8

From no interest (volume) in PBMD for the last few months, the purchases of approx 12,000 PBMD shares (360,000 PRR shares) at rising prices, shows some interest on NASDAQ. Note that there has been negligible trading in PBMD since the Nasdaq listing and perhaps less than 100,000 PRR have been converted into PBMD shares until now.

I am hoping that if there were more sellers of PBMD at current prices they would have been snapped up by buyers.

We are already in mid-Feb, and in the second quarter buying will start as plans for testing CVAC in new indications will be announced anytime during the quarter. If CAN 3 trial and ICS results did not show that over-expressed mucin1 cancer cells were being destroyed, then they would not test Cvac in other mucin1 overexpressing cancer indications. Surely ML and NF know how the trial patients are performing.

Brainy